Drug Respiratory

Ofev

Payments companies reported to CMS as associated with Ofev. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$6.1Massociated payments (2023-2025)

15,422clinicians with associated payments

4companies reporting

By year

2023 $2.9M

2024 $2.3M

2025 $903K

Payments reported as associated with Ofev, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Pulmonary Disease $2.8M

Rheumatology $964K

Critical Care Medicine (Internal Medicine) $425K

Internal Medicine $284K

Family $265K

Pediatric Pulmonology $249K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ofev

These are the largest totals companies reported as associated with Ofev. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Steven Nathan	Falls Church, VA	Pulmonary Disease	$167,804.22
Ayodeji Adegunsoye	Chicago, IL	Pulmonary Disease	$131,281.37
Justin Oldham	Ann Arbor, MI	Pulmonary Disease	$111,500.49
Toby Maher	Los Angeles, CA	Pulmonary Disease	$99,124.58
Shervin Assassi	Houston, TX	Rheumatology	$98,659.72
Elizabeth Volkmann	Los Angeles, CA	Rheumatology	$77,687.52
Joseph Mammarappallil	Durham, NC	Diagnostic Radiology	$75,222.47
Anna Podolanczuk	New York, NY	Critical Care Medicine (Internal Medicine)	$74,339.97
Ara Dikranian	San Diego, CA	Rheumatology	$72,384.89
Rajat Walia	Phoenix, AZ	Pulmonary Disease	$71,936.49

Prescribed Ofev?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.